EITF Proposed Revenue Recognition Rules - Implications For Biotech Companies

Sponsored By BDO Seidman, LLP

Topics:

Accounting > Accounting Standards

Budgeting & Planning > Strategy

Professional Services > Auditing

View White Paper now

Free registration is required

Abstract:

Recently proposed changes by the Emerging Issues Task Force (EITF) to revenue recognition guidance for multiple-element arrangements have generally been well received by companies that offer products and services on a bundled basis. However, biotech industry which relies heavily on long term strategic and collaboration arrangements with pharmaceutical companies to finance product development efforts, may not get as much relief as might be available to their counterparts in the technology sector. Careful planning during contract negotiations and diligent efforts to maintain adequate record during the contract execution phases can help biotech companies navigate through the most significant revenue recognition challenges to avoid complicated and undesirable accounting consequences.

DETAILS

Sponsored by: BDO Seidman, LLP

Released: September 10, 2009

Length: 5 pages

Format: PDF (232 kb)

Email this abstract

These white papers are not created by the CFO.com editorial staff. In order to view these papers, you must register with CFO.com and agree to share your contact information with related product/service companies.

Search White Papers